EFPIA
Europe's pharmaceutical sector is stepping up measures to help deliver faster, more equitable access to medicines for millions of patients across the EU.
The new pledge from the European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies should drastically increase the availability of innovative medicines in EU countries and decrease the time patients must wait for new medicines by several months.
From today EFPIA Member companies commit to file for pricing and reimbursement in all EU countries as soon as possible and no later than 2 years from the central EU market authorisation, provided that local systems allow it. The commitment is designed to help deliver faster, more equitable access to medicines for patients across Europe.
Data published by EFPIA last week showed that disparities in the time it takes for patients to access new medicines in different EU Member States are increasing. Patients in Germany wait around 133 days to access new medicines compared to patients in Romania that endure a wait of 899 days. Significant disparities also occurred in terms of availability of innovative medicines since less than 30% of centrally approved products are available in smaller and Eastern European Member States compared with 92% in Germany and 46% in average in the European Union.
Modelling by IQVIA predicts that the commitment to file would increase the availability of medicines from 18% up to 64% in several countries depending on the country’s payer resource for assessment of the increased number of applications. Critically, the modelling also estimates that the commitment would reduce the time patients wait for new medicines by 4 to 5 months in several countries such as Bulgaria (-179 days), Poland (-129 days) and Romania (-155 days).
However, the time between getting marketing authorisation and companies filing for pricing and reimbursement in a country is just one part of the story. According to analysis by Charles River Associates , there are 10 inter-related factors that cause barriers and delays in patients getting access to new medicines. These causes are rooted in Member States’ access systems and processes and their corresponding impact on commercial decision-making.
This is why the commitment to file is supported by the launch of an online portal where marketing authorisation holders can provide timely information regarding the timing and processing of pricing and reimbursement applications in the EU-27 countries. Bringing greater transparency to the barriers and delays to access will facilitate finding solutions in partnership. Further details of both the commitment to file and the online portal are included in Addressing patient inequalities in Europe , a position paper published by EFPIA today.
In addition to a more equitable system for patients, EFPIA is opening discussions on a more equitable system for EU Members States where the price of innovative medicines can vary between countries depending on their economic level and ability to pay. Also published today, a discussion document entitled ‘A Shared Approach to Supporting Equity-based Tiered Pricing’ sets out the key features of an equity-based tiered pricing system, anchored in the principle of solidarity between Member States and enshrined in the EU treaties. To deliver an equity based, fairer system requires the Commission and Member States to amend external reference pricing systems and undertake mechanisms to prevent the unintended consequences from internal trade in medicines.
Speaking about the launch of the new commitments, EFPIA Director General Nathalie Moll said. “By reducing the time it takes to file for pricing and reimbursement in all 27 EU member States, by bringing greater transparency to the barriers and delays to access, by co-creating an equity-based pricing system, by adopting an efficient system of EU assessments of relative efficacy and by sharing information on the implementation of novel pricing mechanisms, we believe that together we can create a step-change in the access landscape for patients across Europe. ”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220410005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 09:00:00 CET | Press release
Thales launches its new AI Security Fabric, delivering the first runtime security capabilities designed to protect Agentic AI, LLM-powered applications, enterprise data, and identities.New capabilities address emerging AI-specific threats—including prompt injection, data leakage, model manipulation, and insecure RAG pipelines—helping organizations innovate safely while maintaining compliance.With upcoming 2026 enhancements, Thales aims to provide a comprehensive security layer for AI ecosystems, enabling enterprises to confidently scale AI adoption across cloud and on-premises environments. AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in A
Interactive Brokers Adds Access to Brazil’s B3 Exchange11.12.2025 09:00:00 CET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that eligible clients outside of Brazil can now trade Brazilian equities through B3, the Brazil Stock Exchange. This expansion gives investors more ways to access emerging market opportunities across Latin America alongside global stocks, options, futures, currencies, bonds, funds, and more through a single unified platform. The B3 Exchange is one of the most active and liquid markets in the region. With this addition, investors will have direct access to trade Brazilian equities, plus over 160 markets worldwide using Interactive Brokers’ powerful trading platforms and tools. “Global investors need seamless access to diverse markets to stay competitive,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “By adding Brazil’s B3 Exchange, we’re giving our clients efficient, low-cost access to one of the world’s most dynamic emerging economies through our unified global platform.” Int
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman11.12.2025 08:30:00 CET | Press release
Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026Announcement Follows Year of Dual CEO / COO Model and Returns Company to Single Leader Structure Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman. In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin11.12.2025 07:00:00 CET | Press release
Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause and is associated with very high burden of disease due to severe itch, sleep deprivation and mental distress1 Galderma’s phase II study builds on emerging research that reinforces the role of IL-31 – a neuroimmune cytokine that is involved in driving itch – in CPUO1 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-312 It is approved by multiple regulatory authorities for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis – conditions in which IL-31 plays a key role in driving itch, inflammation, epidermal dysregulation, and, in prurigo nodularis, fibrosis2-6 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic P
Ant International and HSBC Test New Cross-Border Payments Solution Using Tokenised Deposits on Swift’s Network and Powered by ISO 2002211.12.2025 04:00:00 CET | Press release
ISO 20022-enabled solution allows blockchain interoperability on Swift’s network, using Ant International’s technology and HSBC’s Tokenised Deposit Service Integration with Swift’s network extends AML and anti-fraud capabilities to tokenised deposits transactions Proof of concept (POC) marks a step towards enabling seamless money movement across borders Ant International, HSBC and Swift today have completed a successful Proof of Concept (POC) for the cross-border transfer of tokenised deposits using ISO 20022 standards. The initiative leverages Swift’s global messaging network and HSBC’s recently launched Tokenised Deposit Service, combined with Ant International’s blockchain technology. The POC marks a key milestone in Ant International, HSBC, and Swift’s efforts to help businesses unlock the full benefits of tokenisation for enhanced liquidity, programmable finance, and 24/7 real-time settlement. As part of this initiative, Ant International and HSBC successfully integrated Ant Inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom